Abpro Holdings, Inc. (ABPO)
| Market Cap | 1.30M -93.6% |
| Revenue (ttm) | n/a |
| Net Income | 2.01M |
| EPS | 0.51 |
| Shares Out | 5.90M |
| PE Ratio | 0.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,558 |
| Open | 0.1943 |
| Previous Close | n/a |
| Day's Range | 0.1943 - 0.22249 |
| 52-Week Range | 0.0866 - 8.2500 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About Abpro Holdings
Abpro Holdings, Inc., a biotechnology company, focuses on the development of novel antibodies using discovery and engineering platforms for immuno-oncology, ophthalmology, and infectious disease in the United States. Its platforms include DiversImmune, an antibody discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides flexibility to combine antibody building blocks in different combinations and orientations to create fit... [Read more]
Financial Performance
Financial StatementsNews
Abpro Holdings Quarterly report: Q2 2026
Abpro Holdings has published its Q2 2026 quarterly earnings report on August 14, 2026.
Abpro Holdings Quarterly report: Q1 2026
Abpro Holdings has published its Q1 2026 quarterly earnings report on May 20, 2026.
Abpro Holdings Annual report: Q4 2025
Abpro Holdings has published its Q4 2025 annual report on April 15, 2026.
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today...
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
FDA clearance enables initiation of Abpro's first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro's global collaboration with Celltrio...
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpr...
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announce...
Abpro Holdings Registration statement: Registration Filing
Abpro Holdings filed a registration statement on November 28, 2025, providing details about a securities offering with the SEC.
Abpro Holdings Registration statement: Registration Filing
Abpro Holdings filed a registration statement on November 7, 2025, providing details about a securities offering with the SEC.
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/...
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq compliance...
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on October 6, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on September 18, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on September 16, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on September 8, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on August 29, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Slides: Investor presentation
Abpro Holdings has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2025.
Abpro Holdings Registration statement: Registration Filing
Abpro Holdings filed a registration statement on June 6, 2025, providing details about a securities offering with the SEC.
Abpro Holdings Registration statement: Registration Filing
Abpro Holdings filed a registration statement on May 22, 2025, providing details about a securities offering with the SEC.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on April 29, 2025, providing details for shareholder voting and corporate governance matters.
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on March 24, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Holdings Proxy statement: Proxy Filing
Abpro Holdings filed a proxy statement on March 13, 2025, providing details for shareholder voting and corporate governance matters.
Abpro Statement on the Departure of Former CEO Ian Chan
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...